Operating Expenses

Acquired IPR&D Expense

AbbVie Acquired IPR&D Expense increased by 200.0% to $744.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2025
Last reportedQ1 2026May 8, 2026
Metric ID: abbv_acquired_iprd_expense

Historical Data

2 periods
 Q1 '25Q1 '26
Value$248.00M$744.00M
QoQ Change—+200.0%
YoY Change—+200.0%
Range$248.00M – $744.00M
Avg YoY Growth+200.0%
Median YoY Growth+200.0%

Acquired IPR&D Expense at Other Companies

Eli Lilly logo
Eli LillyLLYView metric
Pfizer logo
PfizerPFEView metric
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTXView metric
Gilead Sciences logo
Gilead SciencesGILDView metric

Frequently Asked Questions

What is AbbVie's acquired ipr&d expense?
AbbVie (ABBV) reported acquired ipr&d expense of $744.00M in Q1 2026.